IPO - REGENTIS BIOMATERIALS LTD.

Form Type: F-1/A

Filing Date: 2025-05-19

Corporate Action: Ipo

Type: New

Accession Number: 000121390025045479

Filing Summary: Regentis Biomaterials Ltd. filed its Amendment No. 2 to Form F-1 registration statement. This document details an initial public offering (IPO) of 1,000,000 ordinary shares, targeting an anticipated price range between $10.00 and $12.00 per share, with a midpoint assumption of $11.00. The offering will occur as soon as possible following the effective date, pending SEC approval. Regentis, operating under the symbol 'RGNT' on NYSE American, is a regenerative medicine company focusing on orthopedic treatments, notably with its lead product candidate GelrinC, designed for cartilage repair in the knee. GelrinC, a CE-marked product since 2017, aims to address an unmet market need for cartilage injury therapies, promoting regeneration of natural cartilage compared to existing procedures like microfracture surgery. The company acknowledges substantial risks associated with its limited operating history, anticipated continued losses, and dependencies on third parties for clinical development and manufacturing. The document emphasizes potential market opportunities, outlining significant limitations of current industry competitors, stressing GelrinC's advantages and the company's strategy for future product line development.

Form Type: F-1/A

Filing Date: 2025-05-05

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025039589

Filing Summary: Regentis Biomaterials Ltd. has filed an amendment to its Form F-1 registration statement concerning an initial public offering (IPO) of 1,000,000 ordinary shares. The anticipated price for these shares is expected to be between $10.00 and $12.00 each, with the midpoint set at $11.00. The company is seeking to list its shares on the NYSE American under the symbol 'RGNT'. As a foreign private issuer and an emerging growth company, Regentis is subject to reduced disclosure requirements. The document highlights the company's focus on developing innovative tissue repair solutions, particularly in orthopedic treatments utilizing their Gelrin technology, which has shown promise in clinical trials. Notably, GelrinC, their lead product candidate approved in Europe, aims to address knee cartilage injuries. The filing signifies the company's efforts to attract investors to fund its operations and further clinical development. The registration is not yet effective, and the prospectus is not an offer to sell the securities or a solicitation for offers to buy in any jurisdiction where such an offer is not permitted. This amendment reflects an update and is part of the statutory requirement to keep the registration statement up to date as the company prepares for the IPO.

Form Type: F-1

Filing Date: 2025-03-11

Corporate Action: Ipo

Type: New

Accession Number: 000121390025022350

Filing Summary: Regentis Biomaterials Ltd. is registering for an initial public offering (IPO) of ordinary shares, with 909,090 shares planned for offering at an anticipated price range of $10.00 to $12.00 per share. This represents an important step in the company's strategy to commercialize its lead product, GelrinC, for the treatment of knee cartilage injuries. The company emphasizes that it has not previously had a public market for its shares and has applied for listing on the Nasdaq Capital Market. As an emerging growth company, Regentis is subject to reduced public reporting requirements, and the registration is pursuant to the Securities Act of 1933. GelrinC, which utilizes a unique hydrogel technology for cartilage repair, has shown promising results in clinical studies compared to traditional microfracture methods. The offering is expected to raise funds critical for advancing regulatory approvals and future product development.

Form Type: DRS/A

Filing Date: 2025-02-12

Corporate Action: Ipo

Type: New

Accession Number: 000121390025012299

Filing Summary: Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of ordinary shares, par value NIS 0.01 per share. The offering is part of an amendment to a draft registration statement for confidential review under the Jumpstart Our Business Startups Act. The anticipated IPO price range is not provided, but the company plans to list its shares on the Nasdaq Capital Market under the symbol 'RGNT'. The firm aims to address knee cartilage injuries with its product, GelrinC, a hydrogel implant that has received CE mark approval. The company is described as an emerging growth company, emphasizing a product that offers an innovative approach to cartilage repair and meets significant market needs. The document highlights risks involved, including competition and reliance on third parties for clinical trials and manufacturing.

Form Type: DRS/A

Filing Date: 2025-01-27

Corporate Action: Ipo

Type: New

Accession Number: 000121390025006676

Filing Summary: Regentis Biomaterials Ltd. is filing for an initial public offering (IPO) of ordinary shares as detailed in this confidential registration statement submitted to the SEC. The company specializes in regenerative medicine, focusing on innovative solutions for tissue repair, particularly in orthopedic treatments. Their lead product candidate, GelrinC, has shown the potential for treating knee cartilage injuries by regenerating cartilage through a unique hydrogel matrix that facilitates healing without leaving fibrous tissue. The anticipated initial offering price is not finalized, and the company aims to list its shares on the Nasdaq under the ticker 'RGNT'. The document emphasizes the high risks associated with the investment due to the company's limited operating history, anticipated financial losses, and ongoing development efforts, while also highlighting the distinct benefits of GelrinC over current standard procedures such as microfracture surgery. The

Form Type: DRS

Filing Date: 2025-01-24

Corporate Action: Ipo

Type: New

Accession Number: 000121390025006245

Filing Summary: Regentis Biomaterials Ltd. has filed a registration statement for an initial public offering (IPO) of its ordinary shares under the SEC's Regulation D. The filing indicates a firm commitment offering of ordinary shares with an anticipated initial offering price still to be determined. The company is an emerging growth company focused on developing innovative tissue repair solutions, especially for knee cartilage injuries using their proprietary GelrinC hydrogel technology, which aims to provide longer-lasting and more effective treatments compared to current methods. The company plans to list its shares on the Nasdaq Capital Market under the symbol 'RGNT'. The registration is confidential and anticipates sales to commence shortly after approval by the SEC.

Form Type: DRS

Filing Date: 2024-11-21

Corporate Action: Ipo

Type: New

Accession Number: 000121390024101093

Filing Summary: Regentis Biomaterials Ltd., a regenerative medicine company based in Israel, is conducting an initial public offering (IPO) to sell ordinary shares, aiming to raise capital to further develop their proprietary Gelrin technology for treating cartilage injuries. The company has developed GelrinC, a hydrogel product approved for use in Europe, which has shown promising clinical outcomes in repairing knee cartilage compared to traditional methods. The IPO will enable Regentis to conduct additional clinical trials, secure manufacturing capabilities, and engage strategic partnerships. Despite the prospects, the offering poses substantial risks to investors, including the company's operating losses, reliance on third-party service providers, and competition within the industry. There is uncertainty regarding the approval of the shares on the Nasdaq Capital Market, as well as risks associated with financial sustainability, market acceptance, and operational execution. The offering's underwriters are ThinkEquity, who will manage the public sale process.